Literature DB >> 8278013

["Covert criticism"--a new criterion for determining the expressed emotion index in a five-minute speech sample of partners of depressed patients].

B Leeb1, C Mundt, P Fiedler, S Ernst, H Lober, C Münzel.   

Abstract

The expressed emotion (EE) index is a measure of affective attitudes held by relatives toward a mentally ill family member. In several studies it has been shown to be a predictor of relapse in the course of schizophrenia and depression. Since the Camberwell Family Interview (CFI) as the traditional method for assessing EE is time-consuming, a brief method--the Five-Minute Speech Sample (FMSS)--has been developed as an alternative for research and clinical work. The FMSS is also suitable for repeated application. Reliability and concurrent validity of the FMSS-EE have been demonstrated in cross-cultural samples of families with a schizophrenic member. However, application of the FMSS coding system to relatives of depressed patients in our sample proved to be problematic. Criticism, the most important EE-component, could not be assessed using the existing rating procedure. Therefore a modified version of the rating system has been developed. A new category named "covert criticism" has been defined which also includes indirect criticism. In an ongoing study a high degree of interrater reliability was achieved with the new system. Available data concerning concurrent validity indicate that clinically meaningful results can be derived by using the EE-ratings based on "covert criticism".

Entities:  

Mesh:

Year:  1993        PMID: 8278013

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  1 in total

1.  A comparison of expressed emotion between mothers and their adolescent daughters with and without a history of nonsuicidal self-injury.

Authors:  Taru Tschan; Simone Pfeiffer; Raphael Gutzweiler; Tina In-Albon
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2022-08-08       Impact factor: 7.494

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.